Brazil Resolução Gecex nº 779/2025 — Chromium-Sulfate Tariff-Rate Quota, Natural-Rubber Tariff Reduction, and Antibiotic Tariff-Reduction Removal

Mechanism

Resolução Gecex nº 779/2025 is a technical amendment to Resolução Gecex nº 272/2021, the instrument that adapted Brazil's Common Mercosur Nomenclature (NCM) and Common External Tariff (TEC) schedules to the 2022 Harmonized System revision (SH-2022). This is the same recurring TRQ/ex-tarifário maintenance channel used by companion resolutions in the same Gecex 272/2021 family (e.g. nº 799, nº 812, nº 815, nº 816, nº 821, nº 844), approved at the 228th Ordinary Gecex Meeting held 27 August 2025.

Article 1 (Annex I — inclusions, Annex V of Resolução 272/2021):

• Chromium sulfate powder, obtained by inorganic reduction (NCM 2833.29.60,

Ex 001) — new 3.6% duty within a 25,000 tonnes/year quota, valid 1 September 2025–31 August 2026.

• Natural rubber, technically specified (TSNR) (NCM 4001.22.00) — 10.8%

duty, no quota, valid 29 August 2025–28 August 2027.

• Granulated or pressed rubber (NCM 4001.29.20) — 10.8% duty, no quota,

valid 29 August 2025–28 August 2027.

Article 2 (Annex II — exclusions from Annex V): three antibiotic active-ingredient import lines lose their reduced-tariff eligibility and revert to the standard MFN rate:

• Piperacillin/tazobactam combination (NCM 3004.10.19, Ex 001)
• Ceftazidime-containing product (NCM 3004.20.59, Ex 001)
• Meropenem-containing product (NCM 3004.20.99, Ex 001)

The resolution entered into force on its publication date (Art. 4), with the chromium-sulfate quota's own validity window starting 1 September 2025.

Downstream implications

• Chromium sulfate (used in leather tanning and metal-surface treatment) is

a downstream chromium-compound input, not raw chromite ore — the quota gives Brazilian tanning/finishing industries a capped volume of duty-reduced imported supply rather than full liberalisation, consistent with Brazil's narrow, product-specific TRQ housekeeping pattern seen across the Gecex 272/2021 amendment series.

• The natural-rubber additions lower input costs for Brazilian rubber-goods

manufacturers with no annual cap, a more durable liberalising move than the capped chromium-sulfate quota.

• The three antibiotic exclusions raise the landed cost of imported

piperacillin/tazobactam, ceftazidime, and meropenem — active pharmaceutical ingredients with no stated domestic-production justification in the resolution text, shifting cost pressure onto Brazilian generic-drug manufacturers and public procurement (these are hospital-grade antibiotics used against resistant infections).

Open questions

• Whether the antibiotic exclusions reflect a finding of adequate domestic

API production capacity (the standard justification for removing supply-shortage tariff relief) or a different policy rationale — the published resolution text does not state a reason for Annex II removals.

• Fill rate of the 25,000 t/year chromium-sulfate quota, not observable

from public sources without Secex import-licensing data. </content>